Story perspectives

HHS Pushes FDA Testosterone Label Update After Safe Trial

6/20/2026

Summary

Story summary

HHS announced June 18, 2026 it will seek FDA label updates for testosterone.
Secretary Brian J. Christine cited the 2023 TRAVERSE trial of 5,200 men showing no cardiovascular risk increase.
FDA will keep contraindication only for metastatic prostate cancer, require monitoring for BPH, and drop age limits.
HHS proposes an Office of Men’s Health, noting testosterone matched placebo for heart attacks and strokes but raised atrial fibrillation and pulmonary embolism.

1 of 1

Story summary

HHS announced June 18, 2026 it will seek FDA label updates for testosterone.
Secretary Brian J. Christine cited the 2023 TRAVERSE trial of 5,200 men showing no cardiovascular risk increase.
FDA will keep contraindication only for metastatic prostate cancer, require monitoring for BPH, and drop age limits.
HHS proposes an Office of Men’s Health, noting testosterone matched placebo for heart attacks and strokes but raised atrial fibrillation and pulmonary embolism.